Published in Br J Cancer on May 09, 2005
Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A (2011) 3.48
DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer (2007) 2.98
Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology: Theory, Data Acquisition, Analysis, and Examples. Curr Med Imaging Rev (2009) 2.52
Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55). Radiology (2010) 2.32
Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol (2012) 2.01
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol (2008) 1.74
Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res (2009) 1.56
ESR statement on the stepwise development of imaging biomarkers. Insights Imaging (2013) 1.51
Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model. FASEB J (2008) 1.41
Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. Eur Radiol (2012) 1.38
Feasibility of using limited-population-based arterial input function for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced MRI data. Magn Reson Med (2008) 1.30
Imaging ovarian cancer and peritoneal metastases--current and emerging techniques. Nat Rev Clin Oncol (2010) 1.26
A quantitative comparison of the influence of individual versus population-derived vascular input functions on dynamic contrast enhanced-MRI in small animals. Magn Reson Med (2011) 1.18
Improving tumour heterogeneity MRI assessment with histograms. Br J Cancer (2014) 1.18
Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions. Angiogenesis (2010) 1.17
White paper on imaging biomarkers. Insights Imaging (2010) 1.15
Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools? Eur J Nucl Med Mol Imaging (2010) 1.14
Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. Br J Cancer (2012) 1.13
A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging. Br J Cancer (2006) 1.12
Physicochemical and MRI characterization of Gd3+-loaded polyamidoamine and hyperbranched dendrimers. J Biol Inorg Chem (2007) 1.12
Dynamic contrast-enhanced imaging techniques: CT and MRI. Br J Radiol (2011) 1.09
Variations of dynamic contrast-enhanced magnetic resonance imaging in evaluation of breast cancer therapy response: a multicenter data analysis challenge. Transl Oncol (2014) 1.09
Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol (2010) 1.08
Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nat Clin Pract Oncol (2008) 1.08
Hyperpolarized (13)C spectroscopy detects early changes in tumor vasculature and metabolism after VEGF neutralization. Cancer Res (2012) 1.07
Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma. PLoS One (2011) 1.05
Functional imaging in adult and paediatric brain tumours. Nat Rev Clin Oncol (2012) 1.05
The biology underlying molecular imaging in oncology: from genome to anatome and back again. Clin Radiol (2010) 1.04
Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic rats. Neoplasia (2007) 1.04
Imaging response assessment in oncology. Cancer Imaging (2006) 1.03
¹⁸F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer. Eur J Nucl Med Mol Imaging (2010) 1.00
The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. Eur Radiol (2006) 1.00
Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol (2016) 0.99
Dynamic contrast-enhanced magnetic resonance imaging as a predictor of clinical outcome in canine spontaneous soft tissue sarcomas treated with thermoradiotherapy. Clin Cancer Res (2009) 0.98
The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function. Br J Cancer (2012) 0.98
Reproducibility assessment of a multiple reference tissue method for quantitative dynamic contrast enhanced-MRI analysis. Magn Reson Med (2009) 0.97
Vessel caliber--a potential MRI biomarker of tumour response in clinical trials. Nat Rev Clin Oncol (2014) 0.93
Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies? Br J Cancer (2012) 0.93
Morphological, functional and metabolic imaging biomarkers: assessment of vascular-disrupting effect on rodent liver tumours. Eur Radiol (2010) 0.93
Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers. Clin Cancer Res (2014) 0.92
Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs (2008) 0.92
Vascular profile characterization of liver tumors by magnetic resonance imaging using hemodynamic response imaging in mice. Neoplasia (2011) 0.91
The response of RIF-1 fibrosarcomas to the vascular-disrupting agent ZD6126 assessed by in vivo and ex vivo 1H magnetic resonance spectroscopy. Neoplasia (2006) 0.91
Blood vessel morphologic changes depicted with MR angiography during treatment of brain metastases: a feasibility study. Radiology (2007) 0.91
Imaging angiogenesis of genitourinary tumors. Nat Rev Urol (2010) 0.90
Imaging readouts as biomarkers or surrogate parameters for the assessment of therapeutic interventions. Eur Radiol (2007) 0.90
Targeted molecular imaging in oncology: focus on radiation therapy. Semin Radiat Oncol (2008) 0.89
Molecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapy. Acad Radiol (2007) 0.89
Feasibility of using limited-population-based average R10 for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced magnetic resonance imaging data. Magn Reson Imaging (2009) 0.89
DCE@urLAB: a dynamic contrast-enhanced MRI pharmacokinetic analysis tool for preclinical data. BMC Bioinformatics (2013) 0.88
Heterogeneity of tumor vasculature and antiangiogenic intervention: insights from MR angiography and DCE-MRI. PLoS One (2014) 0.88
Dynamic contrast-enhanced 3-T MR imaging in cervical cancer before and after concurrent chemoradiotherapy. Eur Radiol (2012) 0.88
Demonstration of the reproducibility of free-breathing diffusion-weighted MRI and dynamic contrast enhanced MRI in children with solid tumours: a pilot study. Eur Radiol (2015) 0.87
Standardized Index of Shape (SIS): a quantitative DCE-MRI parameter to discriminate responders by non-responders after neoadjuvant therapy in LARC. Eur Radiol (2015) 0.87
Multicentre imaging measurements for oncology and in the brain. Br J Radiol (2011) 0.86
A model-constrained Monte Carlo method for blind arterial input function estimation in dynamic contrast-enhanced MRI: II. In vivo results. Phys Med Biol (2010) 0.85
Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI. Br J Cancer (2005) 0.85
DCE-MRI in hepatocellular carcinoma-clinical and therapeutic image biomarker. World J Gastroenterol (2014) 0.85
A quantitative MRI method for imaging blood-brain barrier leakage in experimental traumatic brain injury. PLoS One (2014) 0.84
A pilot study using dynamic contrast enhanced-MRI as a response biomarker of the radioprotective effect of memantine in patients receiving whole brain radiotherapy. Oncotarget (2016) 0.84
Inhibition of tyrosine kinase receptors by SU6668 promotes abnormal stromal development at the periphery of carcinomas. Br J Cancer (2009) 0.83
Precise measurement of renal filtration and vascular parameters using a two-compartment model for dynamic contrast-enhanced MRI of the kidney gives realistic normal values. Eur Radiol (2012) 0.83
Magnetic resonance perfusion imaging in neuro-oncology. Cancer Imaging (2008) 0.82
Comparison of quantitative parameters in cervix cancer measured by dynamic contrast-enhanced MRI and CT. Magn Reson Med (2010) 0.82
Broadening the scope of image-guided radiotherapy (IGRT). Acta Oncol (2008) 0.81
High-field small animal magnetic resonance oncology studies. Phys Med Biol (2013) 0.81
Multimodality multiparametric imaging of early tumor response to a novel antiangiogenic therapy based on anticalins. PLoS One (2014) 0.81
Applications of molecular imaging. Prog Mol Biol Transl Sci (2010) 0.81
Magnetic resonance imaging: a potential tool in assessing the addition of hyperthermia to neoadjuvant therapy in patients with locally advanced breast cancer. Int J Hyperthermia (2010) 0.81
False-negative MRI biomarkers of tumour response to targeted cancer therapeutics. Br J Cancer (2012) 0.81
Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular Treatments. Pharmaceutics (2012) 0.81
New Perspectives on Predictive Biomarkers of Tumor Response and Their Clinical Application in Preoperative Chemoradiation Therapy for Rectal Cancer. Yonsei Med J (2015) 0.80
MRI for Assessing Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer Using DCE-MR and DW-MR Data Sets: A Preliminary Report. Biomed Res Int (2015) 0.80
Therapeutic implications from sensitivity analysis of tumor angiogenesis models. PLoS One (2015) 0.79
Arterial input function calculation in dynamic contrast-enhanced MRI: an in vivo validation study using co-registered contrast-enhanced ultrasound imaging. Eur Radiol (2012) 0.79
Functional MRI and CT biomarkers in oncology. Eur J Nucl Med Mol Imaging (2015) 0.79
Suppression of vascular enhancement artifacts through the use of a multiband, selectively spoiled radiofrequency excitation pulse. J Magn Reson Imaging (2011) 0.79
Dynamic contrast enhanced MRI detects early response to adoptive NK cellular immunotherapy targeting the NG2 proteoglycan in a rat model of glioblastoma. PLoS One (2014) 0.78
Dynamic contrast-enhanced magnetic resonance imaging: fundamentals and application to the evaluation of the peripheral perfusion. Cardiovasc Diagn Ther (2014) 0.78
Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls. Transl Oncol (2014) 0.78
Translational imaging endpoints to predict treatment response to novel targeted anticancer agents. Drug Resist Updat (2011) 0.78
First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies. Clin Cancer Res (2013) 0.78
Delineation and segmentation of cerebral tumors by mapping blood-brain barrier disruption with dynamic contrast-enhanced CT and tracer kinetics modeling-a feasibility study. Eur Radiol (2007) 0.78
Assessment of repeatability and treatment response in early phase clinical trials using DCE-MRI: comparison of parametric analysis using MR- and CT-derived arterial input functions. Eur Radiol (2015) 0.78
GPU-accelerated compartmental modeling analysis of DCE-MRI data from glioblastoma patients treated with bevacizumab. PLoS One (2015) 0.77
A multi-parametric imaging investigation of the response of C6 glioma xenografts to MLN0518 (tandutinib) treatment. PLoS One (2013) 0.77
Multi-parametric assessment of the anti-angiogenic effects of liposomal glucocorticoids. Angiogenesis (2011) 0.77
DCE-MRI assessment of the effect of Epstein-Barr virus-encoded latent membrane protein-1 targeted DNAzyme on tumor vasculature in patients with nasopharyngeal carcinomas. BMC Cancer (2014) 0.77
(18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors. World J Nucl Med (2012) 0.77
VEGFR2-Targeted Three-Dimensional Ultrasound Imaging Can Predict Responses to Antiangiogenic Therapy in Preclinical Models of Colon Cancer. Cancer Res (2016) 0.77
Phase-based arterial input functions in humans applied to dynamic contrast-enhanced MRI: potential usefulness and limitations. MAGMA (2011) 0.76
Synergistic Effect of Anti-Angiogenic and Radiation Therapy: Quantitative Evaluation with Dynamic Contrast Enhanced MR Imaging. PLoS One (2016) 0.76
Prognostication and response assessment in liver and pancreatic tumors: The new imaging. World J Gastroenterol (2015) 0.76
Imaging in drug development: will it deliver on the promise of personalised medicine? Br J Radiol (2010) 0.75
Assessment of Blood-Brain Barrier Permeability by Dynamic Contrast-Enhanced MRI in Transient Middle Cerebral Artery Occlusion Model after Localized Brain Cooling in Rats. Korean J Radiol (2016) 0.75
A Proposed Paradigm Shift in Initializing Cancer Predictive Models with DCE-MRI Based PK Parameters: A Feasibility Study. Cancer Inform (2015) 0.75
A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer. BMC Cancer (2016) 0.75
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther (2001) 14.78
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging (1999) 13.26
Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging (1997) 6.77
Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology (1994) 3.19
Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging (2002) 2.55
Vascular-targeting therapies for treatment of malignant disease. Cancer (2004) 2.54
Vascular targeting agents as cancer therapeutics. Clin Cancer Res (2004) 2.43
Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol (2003) 2.35
Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr (1991) 2.34
Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR (1984) 2.30
Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol (2000) 2.27
Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn Reson Med (1995) 2.10
Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging (1999) 2.07
Quantitation of blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors. Magn Reson Med (1990) 1.99
Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed (2002) 1.80
Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography. Magn Reson Med (1995) 1.65
Measuring blood volume and vascular transfer constant from dynamic, T(2)*-weighted contrast-enhanced MRI. Magn Reson Med (2004) 1.61
Applications of sliding window reconstruction with cartesian sampling for dynamic contrast enhanced MRI. NMR Biomed (2002) 1.61
Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg (2001) 1.59
Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts. Neoplasia (2001) 1.56
Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst (2002) 1.52
MR imaging of tumor microcirculation: promise for the new millennium. J Magn Reson Imaging (1999) 1.52
Accurate multislice gradient echo T(1) measurement in the presence of non-ideal RF pulse shape and RF field nonuniformity. Magn Reson Med (2001) 1.51
Dynamic magnetic resonance imaging of tumor perfusion. Approaches and biomedical challenges. IEEE Eng Med Biol Mag (2004) 1.51
Improved 3D quantitative mapping of blood volume and endothelial permeability in brain tumors. J Magn Reson Imaging (2000) 1.49
Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR Biomed (2001) 1.48
Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol (2002) 1.47
Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. UK MRI Breast Screening Study Advisory Group. Magn Reson Imaging (2000) 1.47
Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK. Br J Cancer (2003) 1.46
Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics. J Magn Reson Imaging (1997) 1.39
Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging (2004) 1.36
Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol (2001) 1.33
Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol (2003) 1.27
Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer. J Magn Reson Imaging (2000) 1.24
How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des (2003) 1.24
MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report. Eur J Radiol (2000) 1.21
Comparison of dynamic contrast-enhanced MRI with WHO tumor grading for gliomas. Eur Radiol (2001) 1.16
Quantification of endothelial permeability, leakage space, and blood volume in brain tumors using combined T1 and T2* contrast-enhanced dynamic MR imaging. J Magn Reson Imaging (2000) 1.15
Measurement of cerebral blood volume via the relaxing effect of low-dose gadopentetate dimeglumine during bolus transit. AJNR Am J Neuroradiol (1996) 1.12
Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with mr imaging. Radiology (2001) 1.10
Tumor angiogenesis: molecular pathology, therapeutic targeting, and imaging. Acad Radiol (2000) 1.09
Functional magnetic resonance imaging: a review of methodological aspects and clinical applications. J Magn Reson Imaging (2003) 1.08
Antiangiogenic cancer therapy. Semin Cancer Biol (2004) 1.05
Dynamic contrast-enhanced MRI in the differentiation of breast tumors: user-defined versus semi-automated region-of-interest analysis. J Magn Reson Imaging (1999) 1.04
Challenges of PK/PD measurements in modern drug development. Eur J Cancer (2002) 1.04
Quantitative analysis of multi-slice Gd-DTPA enhanced dynamic MR images using an automated simplex minimization procedure. Magn Reson Med (1994) 1.03
Translating basic cancer research into new cancer therapeutics. Trends Mol Med (2002) 1.02
Molecular targeting of angiogenesis. Biochim Biophys Acta (2004) 1.00
Application of magnetic resonance imaging to angiogenesis in breast cancer. Breast Cancer Res (2001) 0.98
Structural, functional, and molecular MR imaging of the microvasculature. Annu Rev Biomed Eng (2003) 0.96
Contrast agents in functional MR imaging. J Magn Reson Imaging (1997) 0.95
A model of the dual effect of gadopentetate dimeglumine on dynamic brain MR images. J Magn Reson Imaging (1999) 0.91
MRIW: parametric analysis software for contrast-enhanced dynamic MR imaging in cancer. Radiographics (1998) 0.89
Comparison of cerebral blood volume measurements using the T1 and T2* methods in normal human brains and brain tumors. J Comput Assist Tomogr (1997) 0.87
Measurement of spin-lattice relaxation times with FLASH for dynamic MRI of the breast. Br J Radiol (1996) 0.87
DCE-MRI in clinical trials: data acquisition techniques and analysis methods. Int J Clin Pharmacol Ther (2003) 0.86
Molecular therapeutics: promise and challenges. Semin Oncol (2004) 0.86
Improving image quality and T(1) measurements using saturation recovery turboFLASH with an approximate K-space normalisation filter. Magn Reson Imaging (2000) 0.86
Vascular endothelial growth factor and its inhibitors. Drugs Today (Barc) (2003) 0.86
Comparative signal intensity measurements in dynamic gadolinium-enhanced MR mammography. J Magn Reson Imaging (1994) 0.85
Mechanisms and therapeutic implications of angiogenesis. Curr Opin Oncol (1996) 0.84
Special techniques for imaging blood flow to tumors. Cancer J (2002) 0.81
Contrast-enhanced magnetic resonance body imaging 5. Top Magn Reson Imaging (2003) 0.79
Size dependence of regional blood flow in murine tumours using deuterium magnetic resonance imaging. Int J Radiat Biol (1991) 0.79
Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays. Nat Biotechnol (2000) 15.79
Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging (1999) 13.26
Quality assessment in health. Br Med J (Clin Res Ed) (1984) 8.78
Oxygenation dependence of the transverse relaxation time of water protons in whole blood at high field. Biochim Biophys Acta (1982) 7.13
Guidelines for the welfare and use of animals in cancer research. Br J Cancer (2010) 6.97
Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol (1989) 6.86
A genome-wide search for human non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2. Nat Genet (1996) 6.58
Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet (2005) 6.18
Ikaros DNA-binding proteins direct formation of chromatin remodeling complexes in lymphocytes. Immunity (1999) 5.50
A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat Biotechnol (2001) 4.66
Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet (1989) 4.42
Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet (2005) 4.12
Inequalities in health care use and expenditures: empirical data from eight developing countries and countries in transition. Bull World Health Organ (2000) 3.86
A motivational interviewing intervention to increase fruit and vegetable intake through Black churches: results of the Eat for Life trial. Am J Public Health (2001) 3.37
In vitro cloning of complex mixtures of DNA on microbeads: physical separation of differentially expressed cDNAs. Proc Natl Acad Sci U S A (2000) 3.26
The Osteopaths Bill. BMJ (1993) 3.16
The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain (1987) 3.15
Magnetic resonance imaging (MRI) of articular cartilage in knee osteoarthritis (OA): morphological assessment. Osteoarthritis Cartilage (2006) 3.12
DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst (1999) 3.07
Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci (1993) 3.07
Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol (1986) 3.07
DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer (2007) 2.98
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res (1997) 2.96
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer (1992) 2.91
Magnetic resonance imaging of extradural blood patches: appearances from 30 min to 18 h. Br J Anaesth (1993) 2.87
A conserved retina-specific gene encodes a basic motif/leucine zipper domain. Proc Natl Acad Sci U S A (1992) 2.79
Accuracy of magnetic resonance imaging in determining cause of sudden death in adults: comparison with conventional autopsy. Histopathology (2003) 2.75
Are cancer cells acidic? Br J Cancer (1991) 2.72
Tired, weak, or in need of rest: fatigue among general practice attenders. BMJ (1990) 2.70
The Fc receptor for IgG on human natural killer cells: phenotypic, functional, and comparative studies with monoclonal antibodies. J Immunol (1984) 2.70
Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol (2000) 2.67
Exotic mice as models for aging research: polemic and prospectus. Neurobiol Aging (1999) 2.59
Physical fitness levels vs selected coronary risk factors. A cross-sectional study. JAMA (1976) 2.57
How should we introduce clinical PET in the UK? The oncologists need to have a view. Clin Oncol (R Coll Radiol) (2004) 2.56
Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain (1996) 2.54
Hepatitis B virus produced by transfected Hep G2 cells causes hepatitis in chimpanzees. Proc Natl Acad Sci U S A (1987) 2.46
Causes and consequences of tumour acidity and implications for treatment. Mol Med Today (2000) 2.44
Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med (2003) 2.44
Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med (2000) 2.37
Comparative human oral clinical pharmacology of cefadroxil, cephalexin, and cephradine. Antimicrob Agents Chemother (1977) 2.23
Simplified chromatographic separation of immunoglobulin M from G and its application to toxoplasma indirect immunofluorescence. J Clin Microbiol (1979) 2.22
Significance of systemic endotoxaemia in inflammatory bowel disease. Gut (1995) 2.21
Early detection of treatment response by diffusion-weighted 1H-NMR spectroscopy in a murine tumour in vivo. Br J Cancer (1996) 2.20
Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst (1996) 2.20
Validation of three food frequency questionnaires and 24-hour recalls with serum carotenoid levels in a sample of African-American adults. Am J Epidemiol (2000) 2.11
Estimation of the hypoxic cell-sensitiser misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography. J Chromatogr (1978) 2.08
Expression of cloned hepatitis B virus DNA in human cell cultures. Proc Natl Acad Sci U S A (1980) 2.08
Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer (2000) 2.07
Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer (1996) 2.06
Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J Neurochem (1992) 2.05
Intensive treatment of multiple myeloma and criteria for complete remission. Lancet (1989) 2.04
Rapid diagnosis of Campylobacter pyloridis infection. Lancet (1986) 2.03
Phase I trial of elactocin. Br J Cancer (1996) 2.01
EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol (1997) 2.00
Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst (2000) 1.99
Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet (1991) 1.95
Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat Med (2001) 1.95
ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res (1991) 1.94
District general managers: should they be medically qualified? Br J Hosp Med (1989) 1.93
Biogenesis of mitochondria: the mitochondrial gene (aap1) coding for mitochondrial ATPase subunit 8 in Saccharomyces cerevisiae. Nucleic Acids Res (1983) 1.89
A second-generation screen of the human genome for susceptibility to insulin-dependent diabetes mellitus. Nat Genet (1998) 1.87
Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res (2001) 1.86
Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys (1994) 1.84
Non-surgical management of early breast cancer in the United Kingdom: radiotherapy fractionation practices. Clinical Audit Sub-committee of the Faculty of Clinical Oncology, Royal College of Radiologists, and the Joint Council for Clinical Oncology. Clin Oncol (R Coll Radiol) (1995) 1.82
Exercise for improving balance in older people. Cochrane Database Syst Rev (2007) 1.81
Recovery of mitogenic activity of a growth factor mutant with a nuclear translocation sequence. Science (1990) 1.81
Further advances in the management of malignant teratomas of the testis and other sites. Lancet (1983) 1.80
Precise estimate of fundamental in-vivo MT parameters in human brain in clinically feasible times. Magn Reson Imaging (2002) 1.80
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer (2009) 1.78
DT-diaphorase and cancer chemotherapy. Biochem Pharmacol (1992) 1.78
Analysis of the signal for attachment of a glycophospholipid membrane anchor. J Cell Biol (1989) 1.77
Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol (2000) 1.77
Creatine deficiency syndrome caused by guanidinoacetate methyltransferase deficiency: diagnostic tools for a new inborn error of metabolism. J Pediatr (1997) 1.76
A multicenter measurement of magnetization transfer ratio in normal white matter. J Magn Reson Imaging (1999) 1.76
Heparan sulfate proteoglycans and cancer. Br J Cancer (2001) 1.75
Dietary change through African American churches: baseline results and program description of the eat for life trial. J Cancer Educ (2000) 1.73
Application of spin-echo nuclear magnetic resonance to whole-cell systems. Membrane transport. Biochem J (1979) 1.73
Human purine nucleoside phosphorylase and adenosine deaminase: gene transfer into cultured cells and murine hematopoietic stem cells by using recombinant amphotropic retroviruses. Mol Cell Biol (1987) 1.73
Characterization of the ABA-deficient tomato mutant notabilis and its relationship with maize Vp14. Plant J (1999) 1.72
Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia (2000) 1.72
Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys (2000) 1.71
The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J (2009) 1.71
Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst (1999) 1.70
Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res (1998) 1.70
Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain (1994) 1.68
Cloned mouse ribonucleotide reductase subunit M1 cDNA reveals amino acid sequence homology with Escherichia coli and herpesvirus ribonucleotide reductases. J Biol Chem (1985) 1.68
Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options. Eur J Cancer (2000) 1.66
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer (2006) 1.66
Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital. Ann Oncol (2005) 1.66
Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography. Magn Reson Med (1995) 1.65
A review of the role of established tumour markers. Ann Clin Biochem (1991) 1.65
Activity of phosphorylase in total global ischaemia in the rat heart. A phosphorus-31 nuclear-magnetic-resonance study. Biochem J (1981) 1.65
Pharmacological modulation of pain-related brain activity during normal and central sensitization states in humans. Proc Natl Acad Sci U S A (2005) 1.65
Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res (1980) 1.64
Noninvasive monitoring of carbogen-induced changes in tumor blood flow and oxygenation by functional magnetic resonance imaging. Int J Radiat Oncol Biol Phys (1995) 1.62
Cloning of human purine-nucleoside phosphorylase cDNA sequences by complementation in Escherichia coli. Proc Natl Acad Sci U S A (1983) 1.61